Due to the ongoing global pandemic Covid-19, ESO and ESMO have taken the decision to convert the 19th ESO-ESMO Masterclass in Clinical Oncology that was scheduled on 6-11 March 2021, into virtual ON-LINE MASTERCLASSES.
We have done our best to design and build a new programme keeping the interactive, international, and collaborative Masterclass spirit which will include prerecorded lectures, live sessions, clinical case presentations and direct contact with the Faculty members.
The online edition will be divided into two parts:
Pre-recorded lectures will be organized into Modules based on tumour type and made available for participants to view in their own time one month before part 2. On completion of each module, participants will be given the opportunity to send questions related to the lectures, that will then be answered Live by the Faculty during part 2.
All modules from part 1 must be completed before part 2.
Online live event with lectures/ live discussion and participants’ case presentations
MCO Coordinator: N Pavlidis, GR
ESO Chair: F. A. Peccatori, IT
ESMO Chair: F. Lordick, DE
Host Chair: E. Felip, ES
Advisors: C. Sessa, CH - R. A. Stahel, CH
AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, lung, genito-urinary and gynaecological. Spotlight sessions will facilitate compact update on different topics related to cancer care.
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairmen and the faculty.
The Masterclass will be entirely in English and fluency in English is necessary for admission.
THE MASTERCLASS IS
• Full immersion
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, gastro-intestinal and lung cancers.
The Masterclass in
The 2021 Masterclass is part of
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
Matti Aapro, Clinique de Genolier, Breast Center, Genolier, CH
Anne Arber, University of Surrey, Faculty of Health and Medical Sciences, Guildford, GB
Jann Arends, Freiburg University Hospital, Dept. of Internal Medicine, Freiburg, DE
Susana Banerjee, The Royal Marsden NHS Trust Foundation, Dept of Gynaecology, London, GB
Giampaolo Bianchini, Ospedale San Raffaele, Dept. of Medical Oncology, Milano, IT
Andrés Cervantes Ruiperez, Hospital Clinico Universitario de Valencia - INCLIVA, Oncology Dept., Valencia, ES
Giuseppe Curigliano, European Institute of Oncology / University of Milan, New Drugs for Innovative Therapies Division, Milano, IT
Sara De Dosso, Oncology Institute of Southern Switzerland (IOSI), Medical Oncology Dpt., Bellinzona, CH
Alexander M.M. Eggermont, Princess Máxima Center for Pediatric Oncology, Surgical Oncology Dpt., Utrech, NL
Alexandru Eniu, Riviera-Chablais Vaud-Valais, Interdisciplinary Oncology Service (SIC), Rennaz, CH
Enriqueta Felip, Vall d'Hebron University Hospital, Dept. of Oncology, Barcelona, ES
Karim Fizazi, Institut Gustave Roussy, Cancer Medicine Dpt., Villejuif, FR
Jordi Giralt, Vall d’Hebron Istitute of Oncology, Radiation Oncology Dpt., Barcelona, ES
Andrew Hoy, Consultant in Palliative Medicine, Epson, UK
Samia Hurst Majno, Université de Genève, Ethics Dpt., Geneve, CH
Simon Joosse, University Medical Center Hamburg-Eppendorf, Dept. of Tumor Biology, Hamburg, DE
Anne Letsch, Universitätsklinikum Schleswig-Holstein, Dept. Internal Medicine, Hematology and Oncology, Kiel, DE
Florian Lordick, University Hospital Leipzig, University Cancer Center Leipzig (UCCL), Leipzig, DE
Xavier Maldonado, Valle de Hebrón Instituto de Oncología, Urology Dpt., Barcelona, ES
Fiona McDonald, The Royal Marsden NHS Foundation Trust, Dept. of Radiotherapy, Sutton Surrey, GB
Wendy Oldenmenger, Erasmus MC Cancer Institute, Medical Oncology Dpt., Rotterdam, NL
Roberto Orecchia, European Institute of Oncology, Scientific Directorate, Milano, IT
Olivia Pagani, Geneva University Hospitals, Medical School, Geneva, CH
Nicholas Pavlidis, University Hospital of Ioannina, Medical Oncology Dpt., Ioannina, GR
Fedro Alessandro Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milano, IT
Giancarlo Pruneri, National Cancer Institute (INT), Pathology Dpt., Milano, IT
Cristiana Sessa, Oncology Institute of Southern Switzerland (IOSI), Gynaecology Dpt., Bellinzona, CH
Rolf A. Stahel, University Hospital Zurich, Comprehensive Cancer Center Zurich, Zurich, CH
Bertrand Tombal, Cliniques Universitaires Saint-Luc, Bruxelles, BE
Christos Toumpanakis, Royal Free Hospital, Centre for Gastroenterology - Neuroendocrine Tumour Unit, London, GB
Eric Van Cutsem, University Hospital Leuven, Digestive Oncology Dpt., Leuven, BE
Ursula Vogl, Ente Ospedaliero Nazionale, Genitourinary Dpt., Bellizona, CH
Claudia Witt, University Hospital Zurich and University of Zurich, Inst. of Complementary and Integrative Medicine, Zurich, CH
Ph: +39 02 85464529
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Fax: +39 02 85464545
Ph: +39 02 85464522
This masterclass has been awarded with 27 ACOE credits. Application for CME recognition has been submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, updates will follow.
Follow updates, send questions and join in the discussions using #ESOexperience on Twitter, Instagram and Facebook.
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
In the event of registrations to events held in partnership with other entities (clearly specified in the title of the event or by sending a request to ESO), please be aware that the partner should be considered joint data controller and that the consents provided to ESO will be transferred to the partner as well. Any subsequent consent modifications will need to be communicated to the partner directly.
PARTICIPANT’S PROFILE OF THE MASTERCLASS CANDIDATE
• Age up to 40 years
• At least 2-3 years’ experience in medical or clinical oncology
• This event is designed to meet the educational needs of participants practicing in Central and Western european countries.
• Involvement in scientific activities
• Intermediate level of English
CLINICAL CASE PRESENTATION
In order to allow interraction, participants will be matched into couples and will have to work togather on a case presentation. This will be presented by both participants during the live part of the online event and commented by a multidisciplinary tumour board made by faculty.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration
THE APPLICATION DEADLINE HAS PASSED (27 DECEMBER 2020)
The ONLINE 19th ESO ESMO Masterclass in Clinical Oncology will be divided into 2 parts:
Pre-recorded lectures will be made available to selected participants from 5th February 2021
Part 1 will be divided into 6 blocks, one for each tumour type and one including topics of general interest. Each block can be viewed in your own time, but all blocks must be viewed before Part 2.
A full detailed programme of Part 1 can be found below.
All participants will be asked to send up to 3 questions, each related to a big killer: the questions will be answered during part 2.
PART 2: (Dates: 6-7 March 2021)
Online live event with lectures on latest updates or specifically related to the region, live discussions (Q&A) and participants’ case presentations in tumour boards.
Part 1 Programme:
Part 1 has 6 blocks:
Block 1) Breast cancer
- Current controversies and challenges in breast cancer surgery – MJ Cardoso, PT
- Systemic treatment of early and advanced triple negative disease – G. Curigliano, IT
- Systemic treatment of HER2+ early and advanced disease – A. Eniu, CH
- Current controversies and challenges in radiotherapy – F. Geara, LB
- Preoperative chemotherapy and biologicals – N. Harbeck, DE
- Systemic treatment of luminal early and advanced breast cancer – O. Pagani, CH
- Molecular diagnostic pathology – G. Pruneri, IT
- Optimal approach in locally advanced disease: ESO-ESMO ABC Guidelines – F. Cardoso, PT
Block 2) Lung cancer
- Multimodality treatment of stage III NSCLC – M. Garassino, IT
- Molecular diagnostic pathology of NSCLC – I. Kern, SI
- Radiotherapy for NSCLC – F. McDonald, UK
- Systemic therapy for NSCLC with oncogenic driver mutations – C. Rolfo, US
- Systemic therapy for NSCLC without oncogenic driver mutations - E. Felip, ES
- Multimodality treatment of SCLC – R. Stahel, CH
- Surgery for early and locally advanced NSCLC – I. Schmitt-Opitz, CH
Block 3) Gastro-intestinal cancer
- Multimodal management of localized rectal cancer – A. Cervantes, ES
- Management of pancreatic cancer – S. De Dosso, CH
- Systemic treatment in advanced oesophageal and gastric cancer – F. Lordick, DE
- Adjuvant treatment in colon cancer – D. Papamichael, CY
- Liquid biopsies in GI tumors – F. Penault-Llorca, FR
- Optimal sequencing of systemic treatment for advanced hepatocellular carcinoma – A. Vogel, DE
- Systemic treatment in advanced colorectal cancer – E. van Cutsem, BE
Block 4) Gynaecological cancer
- Systemic treatment in cervical and endometrial cancer – C. Sessa, CH
- Systemic management of ovarian cancer and inhibitors of Parp – J.B. Vermorken, BE
- Guidelines in endometrial cancer – N. Colombo, IT
Block 5) Genitourinary cancer
- Management of testicular cancer – J. Beyer, CH
- First line endocrine therapy in endocrine sensitive prostate cancer – K. Fizazi, FR
- Localized prostate cancer – J. Khader, JO
- Systemic treatment of bladder cancer – H. Khaled, EG
- Treatment of endocrine resistant and refractory prostate cancer – X. Maldonado, ES
- Metastatic renal cancer: evidence-based treatment – N. Mottet, FR
Block 6) Spotlights
- Communication skills – F. Boyle, AU
- Ethics issues – S. Hurst-Majno, CH
- Breast cancer during pregnancy and fertility preservation – F.A. Peccatori, IT
- Early integration in oncology, supportive and palliative care – S. Bosnjak, RS
- Cancer patients with COVID-19 – M. Garassino, IT
- Nutrition – J. Arends, DE
- Genomic Tests in clinical practice – F. Cardoso, PT
- Cancer in the elderly – M. Aapro, CH
- Immuno-oncology – H.A. Azim Jr., MX
Part 2 Programme:
Day 1 - Saturday 06 March 2021
|08:30||Welcome by ESO and ESMO|
|N. Pavlidis, GR - F. Lordick, DE|
|08:40||Parp inhibitors in BRCA mutation carriers|
|G. Curigliano, IT|
|G. Curigliano, IT - O. Pagani, CH - G. Pruneri, IT - M.J. Cardoso, PT|
|09:45||Clinical Case presentation by participants|
|Group A: O. Pagani, CH - G. Pruneri, IT|
|Group B: G. Curigliano, IT - M.J. Cardoso, PT|
|11:30||Use of systemic treatments in men with non metastatic prostate cancer|
|K. Fizazi, FR|
|K. Fizazi, FR - X. Maldonado, ES - B. Tombal, BE - U. Vogl, CH|
|12:35||Clinical Case presentation by participants|
|Group A: K. Fizazi, FR - B. Tombal, BE
|Group B: U. Vogl, CH - X. Maldonado, ES
Day 2 - Sunday 07 March 2021
|08:30||Staging and iRECIST criteria|
|N. Dan Lin, CH|
|N. Dan Lin, CH - E. Felip, ES - F. McDonald, UK|
|9:15||The role of mutation testing in gynaecological cancer|
|S. Banerjee, UK|
|B. Vermorken, BE - S. Banerjee, UK|
|10:10||Clinical Case presentation by participants|
|Group A (Lung Cancer): N. Dan Lin, CH - E. Felip, ES - F. McDonald, UK|
|Group B (Gynaecological Cancers): B. Vermorken, BE - S. Banerjee, UK|
|11:30||Biomarkers for precision treatment in gastrointestinal tumors|
|H. van Laarhoven, NL|
|H. van Laarhoven, NL - F. Lordick, DE - S. De Dosso, CH
|12:30||Clinical Case presentation by participants|
|Group A: H. van Laarhoven, NL - S. De Dosso, CH|
|Group B: F. Lordick, DE|
|13:30||Closing remarks and awards|
|N. Pavlidis, GR - F. Lordick, DE|